BSETrident Texofab LtdLowNeutral
Announced Thu, 29 May · 20:20 IST

The Board of Directors inter-alia has approved the Appointment of Internal Auditor for the financial year 2025-26.

Management Changes View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

The board of Trident Texofab held a meeting on May 29, 2025 and approved the audited standalone financial results for FY2024-25, which carry an unmodified opinion from statutory auditor Shah Kailash & Associates LLP. The company also appointed M/s. Purushottam Khandelwal & Co. as internal auditor for FY2025-26. Additionally, 4,50,477 warrants were converted into 4,50,477 equity shares at Rs. 70 each (including Rs. 60 premium), with the company receiving Rs. 2.36 crore as the balance 75% payment from non-promoter public allottees, taking the total paid-up equity capital to Rs. 14.51 crore. For FY25, total income rose to Rs. 125.36 crore and profit more than doubled to Rs. 2.51 crore from Rs. 1.08 crore in FY24, giving an EPS of Rs. 2.38. A further 13,93,386 warrants remain pending conversion.

Likely market impact

Strong earnings growth and a clean audit report are positive signals for shareholders. The dilution from warrant conversion is modest (~0.3% expansion of share count), and the remaining convertible warrants could lead to further dilution worth tracking.